OPTIMAL

NCT00874419 📎

Regimen

Experimental
erlotinib
Control
gemcitabine+carboplatin

Population

Chinese advanced EGFR-mut NSCLC

Key finding

mPFS 13.1 vs 4.6 mo, HR 0.16 (0.10-0.26); landmark for Chinese EGFR-TKI 1L

Source: PMID 21783417

Timeline

  • Enrollment start: 2008-08 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.15)
  • CSCO NSCLC 2025 ⚠️ OCR source